JPRN-jRCT2080223964已完成Unknown
Clinical Pharmacology Study of TS-071 in Paediatric Patients with Type 2 Diabetes Mellitus
Taisho Pharmaceutical co., LTD0 个研究点目标入组 18 人开始时间: 2018年7月3日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 9age old 至 <= 17age old（—）
- 性别
- All
入选标准
- •Type 2 diabetes mellitus
- •- HbA1c 6.5% to 10.5%
排除标准
- •- Diabetes mellitus other than type 2
- •- Fasting plasma glucose exceeding 250 mg/dL at the screening test
- •- Concurrent urinary tract infection or genital infection, or a history of repeated occurrences of such infection
研究者
相似试验
未知
4 期
Clinical Pharmaclogical study of TS-071 in Patient With Type 2 Diabetetes Mellitus(Evaluation of glycemic variability using continuous glucose monitoring)Type 2 Diabetes MellitusJPRN-jRCT1080222497Taisho Pharmaceutical co., LTD40
进行中（未招募）
1 期
asal spray (CT001) as pain medication before anesthesia in planned surgical procedures - A study of pharmacokinetics in children and adolescents aged 1-17 yearsEUCTR2021-000137-14-DKCessatech A/S30
撤回
4 期
Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand DiseaseVon Willebrand DiseaseNCT02472665Grifols Therapeutics LLC8
未知
2 期
Phase II/III Study of S-877503 in Pediatric Patients with Attention-deficit/Hyperactivity DisorderJPRN-jRCT2080222070SHIONOGI & CO., LTD.
未知
2 期
Phase II/III Study of S-877503 in Pediatric Patients with Attention-deficit/Hyperactivity Disorder -Long term Extension StudyAttention-deficit/Hyperactivity DisorderJPRN-jRCT2080222071SHIONOGI & CO., LTD.